United States - English - NLM (National Library of Medicine)

atomy co., ltd. - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o), sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - purpose: anticaries uses: aids in the prevention of dental cavities.

United States - English - NLM (National Library of Medicine)

quality care products, llc - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin is indicated for: - management of postherpetic neuralgia in adults - adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as gabapentin, during pregnancy. encourage women who are taking gabapentin during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling the toll free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. risk summary there are no adequate data on the developmental risks associated with the use of gabapentin in pregnant women. in nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic (increased fetal skeletal and visceral abnormalities, and increased embryofetal mortality) when administered to pregnant animals at doses similar to or lower than those used clinically [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data when pregnant mice received oral doses of gabapentin (500 mg/kg/day, 1,000 mg/kg/day, or 3,000 mg/kg/day) during the period of organogenesis, embryofetal toxicity (increased incidences of skeletal variations) was observed at the two highest doses. the no-effect dose for embryofetal developmental toxicity in mice (500 mg/kg/day) is less than the maximum recommended human dose (mrhd) of 3,600 mg/kg on a body surface area (mg/m 2 ) basis. in studies in which rats received oral doses of gabapentin (500 mg/kg/day to 2,000 mg/kg/day) during pregnancy, adverse effect on offspring development (increased incidences of hydroureter and/or hydronephrosis) were observed at all doses. the lowest dose tested is similar to the mrhd on a mg/m 2 basis. when pregnant rabbits were treated with gabapentin during the period of organogenesis, an increase in embryofetal mortality was observed at all doses tested (60 mg/kg, 300 mg/kg, or 1,500 mg/kg). the lowest dose tested is less than the mrhd on a mg/m 2 basis. in a published study, gabapentin (400 mg/kg/day) was administered by intraperitoneal injection to neonatal mice during the first postnatal week, a period of synaptogenesis in rodents (corresponding to the last trimester of pregnancy in humans). gabapentin caused a marked decrease in neuronal synapse formation in brains of intact mice and abnormal neuronal synapse formation in a mouse model of synaptic repair. gabapentin has been shown in vitro to interfere with activity of the α2δ subunit of voltage-activated calcium channels, a receptor involved in neuronal synaptogenesis. the clinical significance of these findings is unknown. risk summary gabapentin is secreted in human milk following oral administration. the effects on the breastfed infant and on milk production are unknown. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for gabapentin and any potential adverse effects on the breastfed infant from gabapentin or from the underlying maternal condition. safety and effectiveness of gabapentin in the management of postherpetic neuralgia in pediatric patients have not been established. safety and effectiveness as adjunctive therapy in the treatment of partial seizures in pediatric patients below the age of 3 years has not been established [see clinical studies (14.2)] . the total number of patients treated with gabapentin in controlled clinical trials in patients with postherpetic neuralgia was 336, of which 102 (30%) were 65 to 74 years of age, and 168 (50%) were 75 years of age and older. there was a larger treatment effect in patients 75 years of age and older compared to younger patients who received the same dosage. since gabapentin is almost exclusively eliminated by renal excretion, the larger treatment effect observed in patients ≥75 years may be a consequence of increased gabapentin exposure for a given dose that results from an age-related decrease in renal function. however, other factors cannot be excluded. the types and incidence of adverse reactions were similar across age groups except for peripheral edema and ataxia, which tended to increase in incidence with age. clinical studies of gabapentin in epilepsy did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values in these patients [see dosage and administration (2.4), adverse reactions (6), and clinical pharmacology (12.3)] . dosage adjustment in adult patients with compromised renal function is necessary [see dosage and administration (2.3)and clinical pharmacology (12.3)] . pediatric patients with renal insufficiency have not been studied. dosage adjustment in patients undergoing hemodialysis is necessary [see dosage and administration (2.3)and clinical pharmacology (12.3)] . gabapentin is not a scheduled drug. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. gabapentin does not exhibit affinity for benzodiazepine, opioid (mu, delta or kappa), or cannabinoid 1 receptor sites. gabapentin misuse and abuse have been reported in the postmarketing setting and published literature. most of the individuals described in these reports had a history of polysubstance abuse. some of these individuals were taking higher than recommended doses of gabapentin for unapproved uses. when prescribing gabapentin, carefully evaluate patients for a history of drug abuse and observe them for signs and symptoms of gabapentin misuse or abuse (e.g., self-dose escalation and drug-seeking behavior). the abuse potential of gabapentin has not been evaluated in human studies. physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. there are rare postmarketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses of gabapentin used to treat illnesses for which the drug is not approved. such symptoms included agitation, disorientation and confusion after suddenly discontinuing gabapentin that resolved after restarting gabapentin. the dependence potential of gabapentin has not been evaluated in human studies.

Kenya - English - Pharmacy and Poisons Board

tramadol hydrochloride - injection - 100mg/2ml - antispasmodics and anticholinergics in

United States - English - NLM (National Library of Medicine)

hello life, inc. - actaea spicata root (unii: 3fu86l9os0) (actaea spicata root - unii:3fu86l9os0), aesculus hippocastanum flower (unii: kk0z92ii8m) (aesculus hippocastanum flower - unii:kk0z92ii8m), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), bellis perennis (unii: 2hu33i03uy) (bellis perennis - unii:2hu33i03uy), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), oyster shell calcium carbonate, crude (unii: 2e32821g6i) (oyster shell calcium carbonate, crude - unii:2e328 - actaea spicata root 10 [hp_x] in 59 ml - actaea spicata hpus.......................................................lameness aesculus hippocastanum hpus........................................numbness arnica montana hpus......................................................stiffness bellis perennis hpus.......................................................soreness bryonia hpus.................................................................headache calcarea carbonica hpus................................................lower back pain calcarea fluorica hpus....................................................back pain causticum hpus............................................................sciatica cimicifuga racemosa hpus.............................................rheumatism formicum acidum hpus..................................................hip and thigh pain hypericum perforatum hpus............................................neuralgia ledum palustre hpus......................................................pain in head lithium carbonicum hpus.

United States - English - NLM (National Library of Medicine)

hello life, inc. - actaea spicata root (unii: 3fu86l9os0) (actaea spicata root - unii:3fu86l9os0), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), bellis perennis (unii: 2hu33i03uy) (bellis perennis - unii:2hu33i03uy), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), oyster shell calcium carbonate, crude (unii: 2e32821g6i) (oyster shell calcium carbonate, crude - unii:2e32821g6i), calcium fluoride (unii: o3b55k4yki) (fluoride ion - unii:q80vpu408o), causticum (unii: dd5fo - actaea spicata root 10 [hp_x] in 59 ml - actaea spicata hpus.........................................pain aesculus hippocastanum hpus.................weakness arnica montana hpus................................soreness bellis perennis hpus............rheumatism symptoms bryonia hpus.............................................stiffness calcarea carbonica hpus.............rheumatoid pains calcarea fluorica hpus................................burning causticum hpus...................................tearing pain cimicifuga racemosa hpus…...............restless limbs formicum acidum hpus...........nodes around joints hypericum perforatum hpus....................cramping ledum paulstre hpus..................................swelling lithium carbonicum hpus....rheumatism symptoms magnesia phosphorica hpus........................spasms phosphorus hpus..........par

United States - English - NLM (National Library of Medicine)

guna spa - althaea officinalis leaf (unii: e2qqv92338) (althaea officinalis leaf - unii:e2qqv92338), antimony potassium tartrate (unii: dl6oz476v3) (antimony cation (3+) - unii:069647rpt5), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), cetraria islandica subsp. islandica (unii: bj7ypn79a1) (cetraria islandica subsp. islandica - unii:bj7ypn79a1), cochineal (unii: tz8z31b35m) (cochineal - unii:tz8z31b35m), copper (unii: 789u1901c5) (copper - unii:789u1901c5), drosera rotundifolia (uni - althaea officinalis leaf 1 [hp_x] in 150 ml - althaea officinalis 1x soothing antimonium tartaricum 8x expectorant cetraria islandica 4x expectorant coccus cacti 6x relieves cough plantago major 1x relieves sore throat bryonia 6x relieves dry cough cuprum aceticum 8x relieves cough drosera 1x relieves dry cough echinacea 1x soothing sticta pulmonaria 4x expectorant thyme 1x soothing - relieves dry and wet cough - helps reduce mucus and phlegm directions: use enclosed cup for dosing.

Canada - English - Health Canada

homeocan inc. - althaea officinalis - tablet - 1dh - althaea officinalis 1dh - homeopathic products

Canada - English - Health Canada

homeocan inc. - actaea spicata - tablet - 1dh - actaea spicata 1dh - homeopathic products

Canada - English - Health Canada

biologische heilmittel heel gmbh - actaea spicata - liquid - 10d - actaea spicata 10d - homeopathic products

Canada - English - Health Canada

biologische heilmittel heel gmbh - actaea spicata - liquid - 4d - actaea spicata 4d - homeopathic products